Skip to main content
. 2011 Mar 17;22(12):2640–2645. doi: 10.1093/annonc/mdr020

Figure 1.

Figure 1.

Thiazolidinediones and metformin are associated with improved survival of diabetic prostate cancer patients. Kaplan–Meier survival curves comparing ever-users and never-users are shown for thiazolidinediones (A), metformin (B), thiazolidinediones and/or metformin (C), insulins and insulin analogues (D), insulin secretagogues (E), and insulins or analogues and/or insulin secretagogues (F). The P values of the log-rank tests are as labeled.